The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors (Q37715991)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2010

Language	Label	Description	Also known as
English	The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors	scientific article published on May 2010

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors (English)

1 reference

Europe PubMed Central

22 August 2017

1 reference

based on heuristic

inferred from title

author name string

Chandra P Belani

1

1 reference

Europe PubMed Central

22 August 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

22 August 2017

Cancer Investigation

1 reference

Europe PubMed Central

22 August 2017

28

1 reference

Europe PubMed Central

22 August 2017

4

1 reference

Europe PubMed Central

22 August 2017

413-423

1 reference

Europe PubMed Central

22 August 2017

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Defining clinically relevant molecular subsets of lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

The development of HKI-272 and related compounds for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

The ErbB receptors and their ligands in cancer: an overview.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study.

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631072

21 January 2018

Identifiers

10.1080/07357901003631072

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37715991&oldid=2104423245"